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Resumo
O Sistema Nacional de Transplantes 
(SNT) Brasileiro coordena e regulamen-
ta o, provavelmente, maior programa de 
transplantes públicos do mundo. Desde 
o seu estabelecimento, em 1997, o nú-
mero de transplantes renais aumentou 
de 920 (5,8 pmp), em 1988, para 4.630 
(24,1 pmp), em 2010. Esse crescimento foi 
primariamente devido ao aumento no nú-
mero de doadores efetivos (de 1,8 pmp em 
1998 para 9,3 pmp em 2010), com aumen-
to correspondente no número de rins trans-
plantados de doadores falecidos (3,8 pmp 
em 1999 versus 9,9 pmp em 2010). O nú-
mero de rins transplantados com órgãos 
de doadores vivos não aumentou signifi-
cativamente, 1.065 (6,7 pmp), em 1998, 
para 1.641 (8,6 pmp), em 2010, tanto em 
consequência do melhor desempenho do 
programa de doadores falecidos, como 
talvez também devido a mais restrita regu-
lamentação, permitindo apenas doação en-
tre doadores vivos relacionados. De 2000 
a 2009, a idade média dos doadores vivos 
aumentou de 40 para 45 anos, e a dos do-
adores falecidos, de 33 para 41 anos, com 
eventos cerebrovasculares sendo responsá-
veis por 50% dos episódios de óbito atu-
almente. Existem disparidades geográficas 
evidentes nos desempenhos entre as 5 regi-
ões nacionais. Enquanto o estado de São 
Paulo ocupa a primeira posição em doação 
e captação de órgãos (22,5 pmp), alguns 
estados da região Norte apresentam peque-
na ou nenhuma atividade de transplante. 
Essas disparidades estão diretamente rela-
cionadas à densidade populacional regio-
nal, ao produto interno bruto e ao número 
de médicos com treinamento em transplan-
te. A avaliação inicial de desfechos clínicos 
robustos não indica diferenças nas sobre-
vidas do enxerto em comparação com as 
AbstRAct
The Brazilian National Transplantation 
System coordinates and regulates per-
haps the largest public transplantation 
program worldwide. Since its imple-
mentation in 1997, the number of kid-
ney transplantations increased from 920 
(5.8 pmp) in 1998, to 4,630 (24.1 pmp) 
in 2010. This growth was primarily due 
to the increased number of effective do-
nors (from 1.8 pmp in 1998 to 9.3 pmp 
in 2010), with a corresponding increased 
number of kidneys transplanted from de-
ceased donors (3.8 pmp in 1999 versus 
9.9 pmp in 2010).The number of kidney 
transplantations from living donors has 
not increased significantly, from 1,065 
(6.7 pmp) in 1998 to 1,641 (8.6 pmp) 
in 2010, either as a consequence of the 
observed increase in the deceased donor 
program or perhaps because of strict 
government regulations allowing only 
transplantations from related donors. 
From 2000 to 2009, the mean age of liv-
ing donors increased from 40 to 45 years, 
while it increased from 33 to 41 years 
for deceased donors, of whom roughly 
50% die of stroke.  There are clear re-
gional disparities in transplantation per-
formance across the national regions. 
While the state of São Paulo is ranked 
first in organ donation and recovery 
(22.5 pmp), some states of the Northern 
region have much poorer performances. 
These disparities are directly related to 
different regional population densities, 
gross domestic product distribution, 
and number of trained transplantation 
physicians.  The initial evaluation of the 
centers with robust outcomes indicates 
no clear differences in graft survival in 
comparison with centers in the USA and 
Europe.  Ethnicity and time on dialysis, 
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IntRoductIon
The Brazilian public health system is characterized 
by free universal coverage, which includes full am-
bulatory and hospital medical care along with pro-
vision of several drugs, including those listed in the 
exceptional drug program, part of the high-com-
plexity outpatient treatment of rare or low-prev-
alence diseases (MS/SAS Ordinance nº 105, from 
29/03/99).1 Two internationally acknowledged ar-
eas belong to this program: organ transplantation 
and treatment of carriers of the human immunode-
ficiency virus (HIV).
The national organ transplantation program is 
probably the largest public transplantation pro-
gram worldwide, with a fair organ allocation lo-
gistics devoid of social or cultural privileges. The 
Ministry of Health (MoH) earmarks approximate-
ly one billion reais for the program each year, the 
money being spent on organ procurement, hospi-
talization for the surgical procedures, hospital re-
admissions for complications, outpatient follow-up 
and provision of immunosuppressors.  Over 95% 
of the transplantations are performed within the 
Brazilian Unified Health System (Sistema Único de 
Saúde – SUS), patients` follow-up being generally 
the responsibility of the transplantation teams.  A 
recent ordinance has regulated the yearly follow-
up of organ donors, determining that coverage be 
equivalent to an outpatient consultation of a trans-
plant recipient.2
development of the tRAnsplAntAtion nAtionAl 
system (sistemA nAcionAl de tRAnsplAntes – snt)
Since its creation, in 1997, the Brazilian transplanta-
tion organization and legislation have been improved 
and regulated, with the yearly establishment of a decen-
tralized network of collaborators, divided in three fully 
integrated hierarchical levels: 1 national level (MoH, 
in Brazilia); 2 regional level, within the structure of 
each State Health Authority; 3 intra-hospital level 
(Figure 1). At the national level, the transplantation 
program is coordinated by the SNT, which is housed in 
the MoH in Brazilia, having been regulated by the Law 
nº 9434, from 04 February, 1997.  The SNT accredits 
teams and hospitals for the peformance of transplanta-
tions, defines financing and oversees ordinances regu-
lating the process, from organ harvesting to the follow-
up of transplant recipients.  The SNT coordinates the 
National Central for Organ Notification, Harvesting 
and Distribution (Central Nacional de Notificação, 
Captação e Distribuição de Órgãos – CNNCDO), 
also in Brazilia, and responsible for organ allocation to 
the states.  The SNT also coordinates the State Organ 
Notification, Harvesting and Distibution Centrals 
(Centrais de Notificação, Captação e Distribuição de 
Órgãos – CNCDO), belonging to the health authori-
ties of the 27 states.3 On the regional level, the state 
centrals coordinate the transplantation activities within 
the state, registering and ranking the recipients, receiv-
ing notifications of potential donors and coordinating 
the whole logistics process, from diagnosis of brain 
observadas nos EUA e na Europa. A etnia e o tempo 
em diálise, mas não o tipo de imunossupressão, apre-
sentam influência decisiva nos desfechos medidos. A 
regulamentação nacional da pesquisa clínica foi imple-
mentada a partir de 1996, permitindo a participação 
de centros brasileiros em numerosos estudos clínicos 
nacionais e internacionais para o desenvolvimento de 
regimes imunossupressores. Acompanhando o desafio 
de atenuar as disparidades regionais no acesso ao trans-
plante, o sistema pode ser aperfeiçoado pela criação 
de um registro nacional para receptores de transplante 
e de doadores vivos de rins e também pela promoção 
de estudos clínicos e experimentais voltados a melhor 
compreender a resposta imune relacionada ao trans-
plante em nossa população.
Palavras-chave: Transplante de Órgãos. Legislação 
Sanitária. Epidemiologia dos Serviços de Saúde. 
Transplante de Rim. Tolerância Imunológica.
but not the type of immunosuppressive regimen, de-
cisively influence the measured outcomes.  Since the 
implementation of national clinical research regula-
tions in 1996, Brazilian centers have participated in 
a number of national and international collabora-
tive trials for the development of immunosuppres-
sive regimens.  Besides the challenge of reducing the 
regional disparities related to access to transplanta-
tion, further improvements can be obtained by the 
creation of a national registry of the outcomes of 
transplanted patients and living donors, and also by 
the promotion of clinical and experimental studies 
to better understand the transplantation-related im-
mune response of the Brazilian population.
Keywords: Organ Transplantation. Legislation, 
Health. Health Services. Epidemiology. Kidney 
Transplantation. Immune Tolerance.
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death, through the approach to the donor`s family , to 
organ harvesting and allocation.  The state health au-
thorities may create organ-procurement organizations 
(organizações de procura de órgãos – OPO), also called 
Organ and Tissue-Procurement Services (Serviços de 
Procura de Órgãos e Tecidos – SPOT), regionalizing 
organ harvesting in densely populated states or in those 
with a large geographical area.  The densely populated 
São Paulo state (40 million inhabitants) has 6 SPOTs, 
4 in the capital only.
Among the several measures implemented to in-
crease the number of potential donors, the 1997-2001 
period saw the regulation of organ harvesting from 
dead donors based on presumed consent, according to 
which, only individuals who had expressely registered, 
in life, their wish not to donate, were not considered 
potential donors.  This way to obtain the family`s au-
thorization for organ harvesting brought discomfort 
to the population and was later revoked.4,5
Between 2001-2010, the family consent for or-
gan donation having been re-established, there was a 
large increase in the absolute and relative numbers of 
transplantations from deceased donors, which was the 
result of a series of other government measures and reg-
ulations, and of the positive incorporation of the trans-
plantation program image into the society`s culture.  A 
significant advance in the process of organ harvesting 
happened following the MoH ordinance nº 1.752, from 
23 September, 2005, which determined that every hos-
pital with more than 80 beds should have an organ do-
nation and tissue transplantation internal commission 
(Comissão Intra-Hospitalar de Doação de Órgãos e 
Tecidos para Transplantes – CIHDOTT), with the aim 
of proactively detecting potential donors.6 Brazil has 
6,489 hospitals (of which, 154 are university hospitals), 
about 2,000 having more than 80 beds.  Of these, 561 
have already defined their internal commissions.  Most 
of these CIHDOTTs are concentrated in Southeastern 
Brazil, 221 being located in São Paulo state.7
An event which occurred in October 2008, in Santo 
André, within the São Paulo metropolitan region (the 
Eloá case), was an example of the need to make the 
population aware of the importance and seriousness 
of the national program of organ transplantation. 
Figure 1. Organization of the national transplantation system.
CNNCDO
National central for organ notication, harvesting and distribution
CIHDOTT 
Intra-hospital commissions 
form donation of organs and 
tissues for transplantation
OPOs 
Organ procurement 
organizations
CIHDOTT 
CNCDOS
Centrals for organ notication, harvesting and distribution
NTS
National Transplantation SystemNacional level Ministry of Health
State level
State Health Authorities
Local level
Hospitals with more than 80 beds
J Bras Nefrol 2011;33(4):472-484 J Bras Nefrol 2011;33(4):472-484  475
Transplante renal no Brasil
This event contributed to the understanding of the 
donation process, as it generated more than 90 thou-
sand pieces of news in 15 days, with permanent me-
dia coverage of the facts that led to the death of a 
15-year-old girl with subsequent organ donation.  All 
medical interventions implemented to avoid the death 
of the patient, who had suffered a gunshot-induced 
cranioencephalic trauma, the means used to diagnose 
brain death, the process of approaching the family 
and counseling it on the donation issue, the family 
decision, the logistics of organ harvesting and allo-
cation to a single list, the destination of the organs 
to different institutions according do the first com-
patible receptor on the waiting list (regardless of the 
receptor`s origin) were all widely broadcast.  Whether 
by coincidence or not, the number of donors in São 
Paulo has significantly increased after that event.
The positive results of the investment and ad-
vancement of the transplantation legislation have 
been clearly demonstrated by the evolution of the na-
tional performance in the past few years. The number 
of transplantations has increased from 920, in 1988, 
to 1,722 (in 1993), 2,394 (in 1999), 3,466 (in 2004) 
and 4,630 (in 2010).8 The living donor/deceased do-
nor ratio remained close to 50% between 1994 and 
2007.  In the past 3 years, the rate of transplantations 
from deceased donors has substantially increased, 
more than 70% of renal transplants in 2010 coming 
from this source (Figure 2).
the need foR tRAnsplAntAtions
The estimated need of organ transplantations per 
million inhabitants and the number of transplanta-
tions performed in 2010 are shown in Figure 3.  The 
number of people presently awaiting transplanta-
tion are 34,640 (kidney), 4,304 (liver), 576 (pancre-
as-kidney), 305 (heart) and 161 (lung).  In several 
Brazilian states, like São Paulo, there is no waiting 
list for corneal transplantation, which must soon be 
the countrywide situation, as there is no age limit 
for cornea donation, and the cornea can be removed 
from almost all donors up to 6 hours after death. 
The large and increasing number of subjects in the 
kidney transplantation waiting list is due to the 
progressive improvement of the quality of life and 
increased life expectation afforded by dialysis, this 
therapeutic option being even better for certain pa-
tient groups.9 Heart, liver and lung transplantations 
are indicated for patients whose life expectation, 
as related to the failing organ, is below 30 months, 
Figure 2. Number of kidney transplantations and Brazilian legislative chronogram during the 1965-2010 period
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which keeps the list small, in comparison with that 
of kidney transplantation, in which subjects may be 
maintained on dialysis for decades.
The demographic profile of candidates to kidney 
transplantation from a deceased donor, in the São 
Paulo state, may be representative of the national av-
erage.  Analysis of 7,123 patients on the kidney trans-
plantation waiting list has shown that 76% of the 
candidates are between 21 and 60 years of age, and 
only 51 are under 18, corresponding to fewer than 
1.5 candidates at the pediatric age range on the wait-
ing list, per million population.10
oRgAn AllocAtion
The allocation of organs from living or deceased do-
nors is regulated by the SNT.  There are no confirmed 
irregularities concerning organ allocation, from living 
or deceased donors, any accusation being readily in-
vestigated by the Prosecution Office.
The allocation of organs from deceased donors 
is controlled by the state centrals, the kidneys being 
allocated according to the best human leukocyte an-
tigen (HLA) matching.  Heart, pancreas and lung are 
allocated according to the time on the waiting list. 
The liver is allocated to the most severely affected pa-
tient on the waiting list, according to the Model for 
End-stage Liver Disease (MELD) score.11 For all the 
organs there are strict circumstantial criteria for pri-
ority attribution under extreme situations.  Patients 
with fulminating hepatitis, in cardiogenic shock, with-
out a vascular or peritoneal access for dialysis, or cor-
nea perforation are prioritized to receive liver, heart, 
kidney and cornea transplants, respectively.  Children 
under the age of 18 years are priorities and compete 
with adults in all situations, having absolute priority 
when the donor matches their age range.12
Between 1999 and 2010, the number of potential 
deceased donors increased 99%, from 18.3/million 
population to 36.4/million population.  The number 
of deceased donors increased 160%, from 3.8/million 
population to 9.9/million population13 (Figure 4). It 
must be highlighted that the profile of the deceased 
donors has progressively changed to become very 
similar to that from international centers.  Data ob-
tained from the São Paulo Health Authority, for the 
2000-2009 period, show an increase in the donors` 
average age, from 33 years, in 2000, to 41 years, in 
2009 (Figure 5).  There was a progressive reduction 
in the number of donors aged under 34 years, whose 
main cause of death is violence,14 and a proportional 
increase in the number of donors aged over 50 years, 
whose main cause of death is stroke.  As an example of 
this shift, the rate of kidney transplantations from ex-
panded criteria donors, defined according to the Organ 
Procurement and Transplantation Network (OPTN),15 
increased from 4%, in 2000, to 31%, in 2010 at the 
Kidney and Hypertension Hospital (Hospital do Rim 
e Hipertensão).  Of the 158 potential donor notifica-
tions received in the first semester of 2010 by the SPOT 
UNIFESP, 49% of the brain death diagnoses were due 
to stroke, 27% to cranioencephalic trauma, 18% to 
anoxia and 5% to other causes.  Donation was per-
formed in 40% of the cases, 22% not happening due 
to lack of authorization by the family.  38% of the po-
tential donors were discarded because of delayed noti-
fication, resulting in cardiac arrest before completion 
of the donation process.10 Nevertheless, in 2010, only 
211 kidneys (12.8%) were rejected as inadequate for 
transplantation, due to impaired kidney function or 
histology.  This rejection rate is lower than that in the 
United States and Spain, where rejection rate is over 
20%.16,17 Faster notification of potential donors must 
not only increase the rate of peformed donations, but 
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Figure 4. Evolution of organ harvesting in Brazil during 
the 1999-2010 period.
Figure 3. Annual transplantation need estimated in 
absolute numbers and per million population (pmp), 
and number of procedures performed in 2010.
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also improve donor maintenance, increasing the viabil-
ity and fuinctional quality of the harvested organs, and 
possibly reducing even more the rejection rate.
The allocation of organs from living donors al-
lows transplantations from up to fourth-degree rela-
tives (first-degree: parents and children; second de-
gree: grandparents and siblings; third-degree: uncles, 
aunts, nephews and nieces; fourth degree: cousins and 
children from consanguineous uncles and aunts), and 
also from spouses.  Transplantation from unrelated 
living donors or friends is only allowed after extensive 
legal analysis, involving medial justification and ethi-
cal and judicial authorization.  The result of this leg-
islation can be seen in Figure 6, which shows donors` 
kinship in 8,711 transplantations performed between 
2005 and 2009 in Brazil.  Whereas most these trans-
plantations were performed between siblings, parents 
and spouses, only 201 (2.3%) kidney transplantations 
were performed with kidneys from friends.
Sensible definition and approach to the selection of 
a live donor are essential for the donor`s safety.  Besides 
the standard clinical and laboratory assessments, the 
birthweight should be considered, as low birthweight 
is related to renal function decline later in life,18 and the 
presence of microalbuminuria, more common in those 
with a single kidney, is an isolated risk factor for the 
development of cardiovascular disease.19
In spite of the growing gap between the number 
of donors and the number of potential recipients on 
the waiting list, organ donation from children to par-
ents, around 100 donors/year (Figure 6), should be 
questioned and intensely debated.  Young age at the 
time of donation, the increasing life expectation and 
the hereditary nature of many renal diseases are risk 
         
         
 
 
 
 
 
 
40.840.439.639.138.137.33734.333.632.9 Mean age
(years)  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
%
 o
f 
do
no
rs
0
5
10
15
20
25
30
35
40
< 18 18 - 34 35 - 49 50 - 64 > 65 
2000 2009 2000 2009 2000 2009 2000 2009 2000 2009 
Figure 5. Distribution of donors according to age range in the 2000-2009 period in São Paulo state.
247 241 
133 
17 
201 
81 16 
421 
1199 
885 
660 
555 
Sib
lin
g
M
ot
he
r
Sp
ou
se
Fa
th
er
Ch
ild
Un
cle
/au
nt
Co
us
in
Fr
ien
d
Ne
ph
ew
/ni
ec
e
Br
ot
he
r-s
ist
er
-in
 la
w
So
n-i
n-l
aw
Gr
an
dp
are
nt
Un
sp
ec
ie
d
4055 
Figure 6.  Kinship between donors and recipients of 
8,711 kidney transplantations performed in the 2005-
2009 period in Brazil.
J Bras Nefrol 2011;33(4):472-484478
Transplante renal no Brasil
J Bras Nefrol 2011;33(4):472-484
factors that may be associated with the development 
and faster progression of renal dieases in donors 
with a single kidney.  This same concept must be em-
ployed in the selection of young donors who have a 
parental history of hypertension, diabetes mellitus or 
early cardiovascular disease, and who may develop 
more accelerated renal disease after donation.
The same profile shift toward an older donor age 
has been observed among living donors, with increas-
ing use of organs from older living donors.  The mean 
age of living donors increased 5 years in the last de-
cade, from 40 to 45 years, living donors over the age 
of 70 years being frequently found.10 The oldest do-
nor at the Kidney and Hypertension Hospital, who 
donated a kidney to her son, at the age of 81, is now 
91 and remains healthy.
Because there is no Brazilian registry of kidney 
donors, it is impossible to assess the repercussions of 
nephrectomy on the function of the remaining kidney 
and on the donor´s survival in the long run.  The liv-
ing donor must be regularly followed up and coun-
seled on hazards such as overweight, hypertension, 
smoking and other habits associated with a higher 
risk of development and progression of renal and car-
diovascular disease.
RegionAl dispARities in the numbeR of 
tRAnsplAntAtions
Although the well established logistics of the SNT has 
resulted in increasing transplantation numbers, there 
are striking regional disparities.  Whereas the perfor-
mance of São Paulo, the Federal District, Rio Grande 
do Sul and Santa Catarina, as regards organ harvest-
ing, is close to that of countries with solid programs, 
in other states, such as Amazon, no organ harvesting 
from deceased donors occurs.
In 2007, the average number of deceased donors 
was 6.2/million inhabitants, ranging from 0 to 14.8 
countrywide. Based on these results, the states were 
grouped according to five categories of organ harvest-
ing performance: I, states with 9-25 effective donors/
million inhabitants; II, with 6-9 donors; III, with 4-6; 
IV, with 2-4; and V, with 0-2 (Figure 7).  Starting 
from these figures, goals for the number of deceased 
donors were set for the next three years.  The three 
states with more than 10 donors/million inhabit-
ants maintained or increased the number of effective 
donors (Santa Catarina, São Paulo and Rio Grande 
do Sul), with three states showing a decline (Rio de 
Janeiro, Mato Grosso and Sergipe).  The performance 
of Paraíba state, with 3.7 million inhabitants, and 
which jumped from category V to category I in three 
years is noteworthy.  This exceptional evolution was 
due to the action of the state government and commit-
ment of the harvesting teams, which liaised to reach 
the proposed goal.
Analysis of kidney transplantations performed in 
2009 in each geographic area showed that most oc-
curred in Southern and Southeastern Brazil.  These 
regions concentrate 57% of the Brazilian popula-
tion, 73% of the Gross Domestic Product (GDP) 
and most professionals affiliated to the Brazilian 
Transplantation Society (Associação Brasileira 
de Transplantes de Órgãos - ABTO)8 (Figure 8). 
These demographic and socioeconomic charac-
teristics directly influence the number of indexed 
scientific publications on organ transplantation, 
80% of which, in the past 10 years, came from the 
Southeast, only 16% coming from the South and 
4% from the other regions.
the são pAulo model
The commitment of the São Paulo government to the 
transplanation program and the reduction of obstacles 
to efficiency were fundamental for the results already 
observed in the state.  The state concentrates 22% of 
the Brazilian population, and 34% of the GDP.  Of 
the 561 CIHDOTTs already set in the country, 221 are 
in São Paulo.  Furthermore, several initiatives toward 
Figure 7. Stratification of the performance of organ 
harvesting in the Brazilian states, according to the rate 
of effective donors per million inhabitants in 2007.  The 
growth goals for 2010 were set from the performance 
of each state in 2007.
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identification of potential donors and performance 
of organ donation have been implemented since 2007 
(Table 1).  The results have been observed in the past 
three years, period during which the number of effective 
donors increased from 10 to 21.2/million inhabitants, 
resulting in 1,439 kidney transplantations performed in 
2010.  This performance is superior to the national aver-
age and close to the averages of the countries with the 
best performances at present: the United States, Portugal 
and Spain20 (Figure 9).  The number of kidney trans-
plantations from living donors is equivalent to that of 
the United States, and the total number of kidney trans-
plantations, from deceased and living donors, is 52/mil-
lion inhabitants, close to the estimated 60/million inhab-
itants/year.  The result of the interventions implemented 
in this state demonstrate the growth potential of the 
national transplantation program, and the possibility of 
reaching the necessary number of transplantations/mil-
lion inhabitants/year in the whole country.
suRvivAl of kidney tRAnsplAnt Recipients
After consolidation of the national transplantation pro-
gram, with implementation of measures to increase its 
efficiency and the number of deceased donors and estab-
lishment of a yearly registry of all activities related to or-
gan and tissue transplantation, the ABTO now embarks 
on a new stage of critically assessing transplantation 
performance in the country.  Nationwide data and data 
from the kidney transplantation centers show increased 
patient and graft survival, a result of consolidation of 
the system (Figure 10).21-24 Allocation of HLA-matched 
kidneys from deceased donors has increased graft sur-
vival in the long run.  In São Paulo state, the survival of 
grafts from deceased donors without HLA-A, HLA-B 
and HLA-DR mismatches was 77.3% by the end of 5 
years of follow-up, while that of grafts with the six hap-
lotype mismatches was 70.9%.10
A special effort should be made to develop and ap-
ply guidelines to the follow-up of specific groups, such 
as black recipients, who have a less favorable evolution 
after kidney transplantation (Figure 11).  There is also 
a need to identify immunosuppressive regimens more 
suitable to the Brazilian population.  Because of the so-
cioeconomic and nutritional features of the population 
on the kidney transplantation waiting list, and the pres-
ence of a number of nationally endemic infections, the 
decision about the immunosuppressive regimen must 
EEG: Eletcroencephalogram; CNCDOs: Centers for Organ Notification, Harvesting and Distribution.
Table 1 list of impRovements to oRgAn hARvesting pRomoted by the são pAulo heAlth AuthoRity since 2007
1. Disponibilization and payment of 7 medical teams for performance of Doppler exams and EEG;
2. Ground transport of the material and team for harvesting outside the municipality;
3. Definition of a support laboratory for serologies;
4. Capacitation and payment of intra-hospital coordinators;
5. Disponibilization of pathology services for assessment of expanded criteria donors;
6. Organization of the CNCDOs with logistic support, trained teams, and internet publication of information;
7. Operational technical support targeting optimization of the performance of the services for organ and tissue procurement;
8. Outcome and survival registry, with the provisioon of data concerning the enrolment of new members in the waiting list.
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consider not only its efficacy against acute rejection, 
but also its long-term safety profile.  This becomes even 
more important when recent studies have suggested 
that there are no patient and graft survival differences 
between kidney transplant recipients on steroids and 
azathioprine/tacrolimus or mycophenolate/tacrolimus 
regimens, pointing to azathioprine as a therapeutic op-
tion for selected patients (Figure 12).25  
tRAnsplAntAtion ReseARch in bRAzil
Research on transplantation has paralleled the im-
provement of the transplantation system.  The ap-
proval of guidelines and norms regulating the de-
velopment of research involving human beings, by 
the Brazilian National Heatlth Council (Conselho 
Nacional de Saúde - CNS), in 1996, originated the 
process of clinical research regulation in the country. 
Creation of the National Commission of Research 
Ethics (Comissão Nacional de Ética em Pesquisa 
- CONEP), to establish guidelines, norms and ethi-
cal standards, and of institutional Research Ethics 
Committees (Comitês de Ética em Pesquisa - CEP), 
with the responsibility of directly monitoring the de-
velopment of projects of research in humans, has wid-
ened the opportunities for liaison among the centers 
and for international collaboration.  In 1987, the first 
phase IV multicenter study was finished in Brazil, and 
in 1999, the first phase III multicenter study involv-
ing two Brazilian centers was concluded.   Around 
3,000 kidney transplant recipients are now included 
in national and/or international multicenter studies, 
definitely situating the Brazilian centers on the inter-
national clinical studies stage.  Brazilian centers par-
ticipate in clinical studies involving everolimus,26-28 
FTY720,29-33 sirolimus,34-36 mycophenolate mofetil,37-41 
mycophenolate sodium,42-44 tacrolimus,45,46 modified-
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Figure 9. Comparison of organ harvesting and number of kidney transplantations performed (pmp) in Brazil, São 
Paulo state, United States, Portugal and Spain.
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Figure 10. Graft (A) and patient (B) survival among 
kidney transplant recipients in Brazil, according to the 
date of transplantation.
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Figure 11.  Graft survival among kidney transplant 
recipients from living and deceased donors, at the 
Kidney and Hypertension Hospital, during the 1999-
2008 period, according to recipient ethnicity.
release tacrolimus,47,48 valgancyclovir,49 belatacept,50 
sotrastaurine (clinicaltrials.gov NCT00504543 e 
NCT01064791) and JAK3 CP690,550 inhibitor 
(clinicaltrials.gov NCT00483756).
Brazil has also made advances in the develop-
ment of experimental research projects involving 
transplantation immunology.  The main lines of in-
vestigation include methods for the early diagnosis 
of acute graft rejection,51-53 non-invasive monitoring 
of the immune response,54 advances in the under-
standing of the molecular and cellular mechanisms 
involved in the ischemia and reperfusion injury,55-57 
and in human operational tolerance.58
peRspectives
Brazil has experimented advances in its social orga-
nization, which can be evidenced by an increased 
life expectation at birth (76 years for women and 69 
years for men),59 a decreased birth rate (reduced from 
5.6 to 2.1 in the past 30 years),60 reduced infant mor-
tality rate, and reduced urban violence and number 
Figure 12.  Graft survival among kidney transplant 
recipients from living (A) and deceased (B) donors, at 
the Kidney and Hypertension Hospital, according to 
the immunosuppressive regimen used.
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of violent deaths (from 13,257 in 1999 to 4,436, in 
2007, in São Paulo).61 In this context, the Brazilian 
transplantation program is an advanced, organized, 
fair and egalitarian system, that must be preserved as 
a national high-complexity medical asset and interna-
tional reference for the Brazilian public health.
This analysis shows a large geographical disparity 
among the transplantation metric variables, which 
may be understood as a consequence of the intrinsic 
regional differences related to access to and qual-
ity of health care.  This scenery, however, may be 
changed with commitment from state governments, 
society in general and transplantation teams.  Proof 
of the effectiveness of these strategies comes from 
Paraíba state, which experienced a striking increase 
in the number of transplantations in a short period 
(3 years), thanks to liaison of the government with 
the transplantation teams.
In spite of the geographical disparities, the na-
tional transplantation program has matured and 
improved.  Besides the continuous effort toward a 
larger number of donors, several other points must 
be considered in the process of organ allocation, 
targeting the improvement of long-term outcomes. 
Finally, we highlight three needs.  Firstly, to sup-
port pre-emptive transplantation, once better results 
have been clearly demonstrated for the population 
receiving this strategy.  While implementation of 
this strategy may be easier for recipients of living 
donors, more discussion is necessary for its imple-
mentation in patients waiting for an organ from a 
deceased donor.  At present, inclusion in the wait-
ing list is restricted to patients with creatinine clear-
ance under 10 mL/min. Secondly, to better identify 
and select patients who will experiment real benefits 
with kidney transplantation in comparison with di-
alysis (Figure 13).  Thirdly, to promote clinical and 
experimental studies in the Brazilian population to 
widen our understanding of the immune response 
and to assess the influence of endemic infections. 
These approaches may improve the outcomes of spe-
cific groups, such as blacks, whose immune response 
modulation requires greater monitoring.
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